MBMarika Bajc

Marika Bajc

*This is an algorithmically generated author record based on publicly available information.

Marika Bajc has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of Ventilation and Perfusion in Patients with COVID-19 Discloses Unique Information of Pulmonary Function to a Clinician: Case Reports of V/P SPECT

    by Marika Bajc, Fredrik Hedeer, Ari Lindqvist, Elin Trägårdh

    V/P SPECT from 4 consecutive patients with COVID-19 suggests that ventilation and perfusion images may be applied to diagnose or exclude pulmonary embolism, verify nonsegmental diversion of perfusion from the ventilated areas (dead space ventilation) that may represent inflammation of the pulmonary vasculature, detect the reversed mismatch of poor ventilation and better preserved perfusion (shunt perfusion) in bilateral pulmonary inflammation and indicate redistribution of lung perfusion (antigravitational hyperperfusion) due to cardiac congestion. V/P mismatch and reversed mismatch may be extensive enough to diminish dramatically preserved matching ventilation/perfusion and to induce severe hypoxemia in COVID-19.


  • Open Access

    Letter to editor

    by Marika Bajc, Björn Jonson

  • Top Cited Papers
    Open Access

    EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond

    by Marika Bajc, Carl Schümichen, Thomas Grüning, Ari Lindqvist, Pierre-Yves Le Roux, Adriano Alatri, Ralf W. Bauer, Mirza Dilic, Brian Neilly, Hein J. Verberne, et al.

    These guidelines update the previous EANM 2009 guidelines on the diagnosis of pulmonary embolism (PE). Relevant new aspects are related to (a) quantification of PE and other ventilation/perfusion defects; (b) follow-up of patients with PE; (c) chronic PE; and (d) description of additional pulmonary physiological changes leading to diagnoses of left ventricular heart failure (HF), chronic obstructive pulmonary disease (COPD) and pneumonia. The diagnosis of PE should be reported when a mismatch of one segment or two subsegments is found. For ventilation, Technegas or krypton gas is preferred over diethylene triamine pentaacetic acid (DTPA) in patients with COPD. Tomographic imaging with V/PSPECT has higher sensitivity and specificity for PE compared with planar imaging. Absence of contraindications makes V/PSPECT an essential method for the diagnosis of PE. When V/PSPECT is combined with a low-dose CT, the specificity of the test can be further improved, especially in patients with other lung diseases. Pitfalls in V/PSPECT interpretation are discussed. In conclusion, V/PSPECT is strongly recommended as it accurately establishes the diagnosis of PE even in the presence of diseases like COPD, HF and pneumonia and has no contraindications.


  • Open Access

    Identifying the heterogeneity of COPD by V/P SPECT: a new tool for improving the diagnosis of parenchymal defects and grading the severity of small airways disease

    by Marika Bajc, Yang Chen, Jun Wang, Xiang Yan Li, Weimin Shen, Changzheng Wang, Hai Huang, Ari Lindqvist, Xiao Yan He

    Introduction: Airway obstruction and possible concomitant pulmonary diseases in COPD cannot be identified conventionally with any single diagnostic tool. We aimed to diagnose and grade COPD severity and identify pulmonary comorbidities associated with COPD with ventilation/perfusion single-photon emission computed tomography (V/P SPECT) using Technegas as the functional ventilation imaging agent. Methods: 94 COPD patients (aged 43–86 years, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages I–IV) were examined with V/P SPECT and spirometry. Ventilation and perfusion defects were analyzed blindly according to the European guidelines. Penetration grade of Technegas in V SPECT measured the degree of obstructive small airways disease. Total preserved lung function and penetration grade of Technegas in V SPECT were assessed by V/P SPECT and compared to GOLD stages and spirometry. Results: Signs of small airway obstruction in the ventilation SPECT images were found in 92 patients. Emphysema was identified in 81 patients. Two patients had no signs of COPD, but both of them had a pulmonary embolism, and in one of them we also suspected a lung tumor. The penetration grade of Technegas in V SPECT and total preserved lung function correlated significantly to GOLD stages (r=0.63 and −0.60, respectively, PConclusion: V/P SPECT, using Technegas as the functional ventilation imaging agent, is a new tool to diagnose COPD and to grade its severity. Additionally, it revealed heterogeneity of COPD caused by pulmonary comorbidities. The characteristics of these comorbidities suggest their significant impact in clarifying symptoms, and also their influence on the prognosis.


  • Comment on “State-of-the-Art Imaging in Pulmonary Embolism: Ventilation/Perfusion Single-Photon Emission Computed Tomography versus Computed Tomography Angiography—Controversies, Results, and Recommendations from a Systematic Review”

    by Thomas Grüning, Marika Bajc

    Hess et al[1] believe that ventilation/perfusion scintigraphy with single-photon emission computed tomography and low-dose X-ray computed tomography (V/Q SPECT/CT) should be considered the first-line imaging modality for diagnosing pulmonary embolism (PE) in most clinical settings, based on overall better diagnostic performance. We believe that this conclusion is not substantiated by the data presented in their meta-analysis: First, there was no significant difference in the diagnostic performance of V/Q SPECT and V/Q SPECT/CT in the studies included (although there was only a single study included for V/Q SPECT/CT, and another study included from the same group dealing with planar and V/Q SPECT). Second, the authors did not include several studies that met their inclusion criteria. In a study on V/Q SPECT based on 1,785 patients with suspected PE who underwent clinical follow-up, PE was reported in 607 patients (34%).[2] In 608 patients with a final diagnosis of PE, 601 patients had positive V/Q SPECT (99%). In 1,177 patients without a final diagnosis of PE, 1,153 patients had negative V/Q SPECT (98%). The report was nondiagnostic in 19 patients (1%). Six cases were classified as false negative for PE, because PE was diagnosed at follow-up and was fatal in one case. Six cases were classified as false-positive for PE because the clinician decided not to treat. In addition, in this study, 152 patients had both CTA and V/Q SPECT, due to continuing clinical suspicion of PE after the first test. In this subgroup, CTA showed a sensitivity of 43% and specificity of 73%, measured against a decision to treat, while V/Q SPECT had a sensitivity of 97% and specificity of 89%. CTA applied as second procedure had a low diagnostic impact in this and a previous study.[3] The authors[1] also did not include, in their meta-analysis, another study that involved almost 2,000 patients, and which showed that sensitivity, specificity, and positive and negative predictive values of V/Q SPECT against a composite reference standard were all greater than 95%.[4] The authors[1] also cite data from 81 patients simultaneously imaged with V/Q SPECT and V/Q SPECT/CT, 38% of which had PE.[5] They showed 97% sensitivity and 88% specificity when only V/Q SPECT was used. However, when adding low-dose CT, the sensitivity was unchanged, but specificity increased to 100%. Interestingly, 18% of patients had a false-positive diagnosis of PE when V/Q SPECT alone was interpreted. A reason for this may be that every mismatch was interpreted as PE rather than only mismatches that conform to segmental lung anatomy, as recommended by European guidelines.[6] [7] In our opinion, the recommendation to use a hybrid system for PE diagnosis is premature. Coco and O'Gurek[8] showed that CT utilization has increased dramatically in the evaluation of patients with suspected PE, without improving the rate of PE or other clinically significant diagnoses. Moreover, patients are exposed to ever greater radiation doses from imaging.[9] Therefore, it is important to properly validate V/Q SPECT/CT and not adopt it too quickly, without fully assessing the benefits and risks.


  • Ancillary findings assessed by ventilation/perfusiont omography

    by A. Begic, E. Opankovic, V. Cukic, A. Lindqvist, M. Miniati, M. Bajc

    Ventilation/perfusion tomography (V/P SPECT) is a recommended method for diagnosing and follow-up of pulmonary embolism (PE). Moreover, it is possible to recognize other pathologies in addition to PE, such as pneumonia, COPD and left heart failure (LHF). The objective of this prospective study was to identify frequency of ancillary findings among patients with suspected PE. Patients, material, method: 331 consecutive patients with suspected PE were examined and classified with V/P SPECT. Patients were followed up clinically and by means of other laboratory tests. Results: 80 patients had a normal V/P SPECT and no clinical consequences in the follow-up. PE had 104 patients: 23 of them had also additional findings. Among the remaining 147 patients, pneumonias were shown in 82, acute in 75 patients and 7 had chronic post inflammatory state. COPD was present in 42 patients, in 3 combined with pneumonia. Sign of LHF was observed in 10: in 7 the acute LHF diagnosis was established, 3 were classified as having a chronic cardiopulmonary disease. Furthermore, in 16 patients, the V/P pattern was suggestive of a tumour. The clinical outcomes were 6 lung tumours, 3 empyema, one sarcoidosis, 2 were unclarified and 4 were lost in the follow-up. Conclusion: V/P SPECT identifies a high prevalence of other cardiopulmonary diseases among patients with a clinical suspicion of PE. Ancillary findings with V/P SPECT clarified patients' symptoms and had an impact on the treatment. These findings were verified by a clinical outcome by the follow-up over three months. Die Ventilations-Perfusionstomographie (V/PSPECT) ist ein für die Diagnose und Verlaufskontrolle der Lungenembolie (LE) empfohlenes Verfahren. Außer einer LE können auch andere Krankheitsbilder erkannt werden, z. B. Pneumonie, COPD oder Linksherz insuffizienz (LHI). Ziel dieser prospektiven Studie war es, die Häufigkeit von Nebenbefunden bei Patienten mit Verdacht auf (V.a.) LE festzustellen. Patienten, Material, Methoden: 331 konsekutive Patienten mit V.a. LE wurden mittels V/P-SPECT untersucht und klassifiziert. Sie wurden klinisch und mit anderen Labormethoden nachuntersucht. Ergebnisse: Bei 80 Patienten war die V/P-SPECT bei der Nachuntersuchung normal und ohne klinische Konsequenz. 104 Patienten hatten eine LE, davon 23 zusätzlich einen Nebenbefund. Unter den verbleibenden 147 Patienten hatten 82 eine Pneumonie, davon 75 Patienten i akuten und 7 im chronisch post-inflammatorischen Stadium. Eine COPD lag bei 42 Patienten vor, bei 3 kombiniert mit Pneumonie. Anzeichen für eine LHI wurden bei 10 beobachtet: bei 7 wurde eine akute LHI diagnostiziert, 3 wurden als chronische kardiopulmonale Erkrankung klassifiziert. Ferner deutete das V/P-Muster bei 16 Patienten auf einen Tumor hin. Klinisch ergaben sich 6 Lungentumore, 3 Empyeme, eine Sarkoidose, 2 blieben unklar und 4 konnten nicht nachuntersucht werden. Schlussfolgerung: Mit V/P- SPECT wird bei Patienten mit V.a. LE eine hohe Prävalenz anderer kardiopulmonaler Erkrankungen entdeckt. Die Nebenbefunde aus der V/P-SPECT konnten die Symptome klären und wirkten sich auf die Behandlung aus. Diese Befunde wurden in einem dreimonatigen Follow-up durch den klinischen Verlauf verifiziert.